Inoue, Yuichi
Uchiyama, Makoto
Umeuchi, Hideo
Onishi, Koichi
Ogo, Hiroki
Kitajima, Iwao
Matsushita, Isao
Nishino, Izumi
Uchimura, Naohisa
Article History
Received: 16 July 2021
Accepted: 9 February 2022
First Online: 22 February 2022
Declarations
:
: These two clinical trials have been performed in accordance with the Declaration of Helsinki. The institutional review board of each site approved the study protocol (Additional file InternalRef removed), and all patients and/or legal guardians provided written informed consent for study participation. This study was conducted following the CONSORT guidelines.
: Not Applicable.
: Yuichi Inoue reports that he and his department have received research support (grants) from Philips Japan Co., Ltd. and KOIKE Medical Co., Ltd.; in addition, he has provided speaking and consulting services to and received personal fees from Eisai Co., Ltd., provided speaking services and received personal fees from Otsuka Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd., Astellas Pharma Inc., and MSD K.K.; and provided consulting services and received personal fees from Taisho Pharmaceutical Co., Ltd. Makoto Uchiyama reports that he and his department have received grants from Astellas Pharma Inc., Eisai Co., Ltd., Meiji Seika Pharma Co., Ltd., Mochida Pharmaceutical Co., Ltd., Merck Sharp & Dohme, Pfizer Inc., Sanofi S.A., Takeda Pharmaceutical Co., Ltd., and Yoshitomiyakuhin Corporation; in addition, he has provided consulting services and received personal fees from Janssen Pharmaceutical K.K., Kao Corporation, Shionogi & Co., Ltd., and Taisho Pharmaceutical Co., Ltd. Hideo Umeuchi, Koichi Onishi, Hiroki Ogo, Iwao Kitajima, Isao Matsushita, and Izumi Nishino are employees of Taisho Pharmaceutical Co. Ltd. Naohisa Uchimura reports receiving grants from Eisai Co., Ltd., Otsuka Pharmaceutical Co., Ltd., Merck Sharp & Dohme, and Takeda Pharmaceutical Co., Ltd.; in addition, he has provided consulting services to and received personal fees from Taisho Pharmaceutical Co., Ltd.